摘要
目的探讨阿仑膦酸钠（福善美）强骨胶囊及二者合用对维甲酸致骨质疏松性大鼠骨折的影响。方法通过维甲酸80mg·kg^-1·d^-1灌胃15d制造实验性雌性sD大鼠骨质疏松模型65只，5只经确认造膜成功后，剩余60只随机分成4组（每组15只）。用咬骨钳造成右侧股骨骨折，用克氏针髓内固定，术后第2天分别给予灌胃对照组生理盐水8ml·kg^-1·W^-1，福善美40mg·kg^-1·W^-1，强骨胶囊90mg·kg^-1·d^-1及二者合用，并分别于2、4、6周处死并行X线检查，取右侧股骨标本行组织学检查，另取左侧股骨给予生物力学测试以了解福善美和强骨胶囊对实验性骨质疏松性大鼠的生物力学影响。结果4周时二者单用或合用均能改善骨质疏松大鼠股骨的生物力学性能（25．2±4．8，23．7±1．2，26.7±2．8，26．5±3．8，P〈0．05），合用不好于单用；4周时福善美x线骨痂测量较大（P〈0．05）；抑制破骨细胞明显，骨痂生长塑形稍慢。强骨胶囊x线骨痂测量较小（P〈0．05）；可见加速编织骨向板状骨转换。结论福善美和强骨胶囊及二者合用均能增加维甲酸所致的骨质疏松性大鼠股骨的生物力学性能。强骨胶囊能促进维甲酸所致的骨质疏松性大鼠股骨骨折愈合。
Objective To study the effectiveness of retinoic acid on induction of osteoporotic rats treated by either alendronate or Qianggu capsules and co-administration. Methods Sixty-five female SD rats were treated with retinoic acid 80 mg·kg^-1·d^-1 by gastric lavage for 15 days. Then 5 rats were confirmed cases of osteoporosis and the remaining 60 were randomly divided into 4 groups 15 each ： （ 1 ） control group with NS 8 mg·kg^-1·W^-1; （ 2 ） alendronate group with alendronate 450mg·kg^-1·W^-1 ; （ 3 ） qianggu group with Qianggu capsules 90 mg·kg^-1·d^-1 ; （4） co-medicated group with alendronate 40mg·kg^-1·w^-1 and Qianggu capsules 90mg·kg^-1·d^-1. Five rats in each group were sacrificed at week 2, 4 and 6 respectively to carry out the biomechanic tests, histopathologic examination and bony callus volume calculation. Results Biomechanical properties of femur changed significantly after the treatment by alendronate or Qianggu capsules and co-medication as compared with that of NS after 4 weeks （P 〈 0. 05 ） ; the bony callus were larger when treated by alendronate （ P 〈 0.05 ） and smaller by Qianggu capsules （ P 〉 0. 05）; the bone trabecula formed and rebuilding were slower by alendronate and quicker by Qianggu capsules. Conclusion Alendronate or Qianggu capsules and co-medication can improve biomechanical properties of femur by retinoic acid on induction of osteoporotic rats. Qianggu capsules can improve bone union.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2009年第27期1930-1933,共4页
National Medical Journal of China
基金
浙江省医学会临床科研基金（2006ZYC12）
